In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.
In the latest edition of Journal of Clinical Pathways, Precision experts Chris Dillon, Chrysanthe Peteros and Larry Blandford examine the expanding role of hub support services in the pharmaceutical marketplace, emphasizing their importance as increasingly complex therapies requiring higher degrees of specialization and flexibility are launched.
A Precision-led study recently published in ISPOR’s Value in Health examines whether budget impact models typically overestimate or underestimate real-world budget impact. PHE study authors Julia Snider, Jesse Sussell, Mahlet Tebeka, Alicia Gonzalez along with scientific advisor Peter Neumann focused on 6 ICER- BIM estimates—comparing each with ex-post estimates and determined that estimates of uptake were substantially higher than ex-post market-based estimates of use.
In a new podcast appearing on the American Journal of Managed Care (AJMC)’s Managed Care Cast, PHE Senior Research Economist James Baumgardner discusses his research on using cost variation to identify savings Opportunities under the Oncology Care Model (OCM).
A new study by Precision co-authors Andrew Delgado and Jinjoo Shim, along with scientific advisors John Romley and Katherine Batt, assesses the value to society of improved survival from novel immune-oncology treatments. With the data compiled, the study team concluded that there is evidence of substantial survival gains, and thus, social value.
For more information, or to learn how to change your cookies preferences, please click here.